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Abstract
Viruses in the Flavivirus genus of the Flaviviridae family are arthropod-transmitted and contribute to staggering numbers of
human infections and significant deaths annually across the globe. To identify cellular factors with antiviral activity against
flaviviruses, we screened a cDNA library using an iterative approach. We identified a mammalian Hsp40 chaperone protein
(DNAJC14) that when overexpressed was able to mediate protection from yellow fever virus (YFV)-induced cell death.
Further studies revealed that DNAJC14 inhibits YFV at the step of viral RNA replication. Since replication of bovine viral
diarrhea virus (BVDV), a member of the related Pestivirus genus, is also known to be modulated by DNAJC14, we tested the
effect of this host factor on diverse Flaviviridae family members. Flaviviruses, including the pathogenic Asibi strain of YFV,
Kunjin, and tick-borne Langat virus, as well as a Hepacivirus, hepatitis C virus (HCV), all were inhibited by overexpression of
DNAJC14. Mutagenesis showed that both the J-domain and the C-terminal domain, which mediates self-interaction, are
required for anti-YFV activity. We found that DNAJC14 does not block YFV nor HCV NS2-3 cleavage, and using non-
inhibitory mutants demonstrate that DNAJC14 is recruited to YFV replication complexes. Immunofluorescence analysis
demonstrated that endogenous DNAJC14 rearranges during infection and is found in replication complexes identified by
dsRNA staining. Interestingly, silencing of endogenous DNAJC14 results in impaired YFV replication suggesting a
requirement for DNAJC14 in YFV replication complex assembly. Finally, the antiviral activity of overexpressed DNAJC14
occurs in a time- and dose-dependent manner. DNAJC14 overexpression may disrupt the proper stoichiometry resulting in
inhibition, which can be overcome upon restoration of the optimal ratios due to the accumulation of viral nonstructural
proteins. Our findings, together with previously published work, suggest that the members of the Flaviviridae family have
evolved in unique and important ways to interact with this host Hsp40 chaperone molecule.
Citation: Yi Z, Sperzel L, Nu ¨rnberger C, Bredenbeek PJ, Lubick KJ, et al. (2011) Identification and Characterization of the Host Protein DNAJC14 as a Broadly Active
Flavivirus Replication Modulator. PLoS Pathog 7(1): e1001255. doi:10.1371/journal.ppat.1001255
Editor: Michael S. Diamond, Washington University School of Medicine, United States of America
Received August 6, 2010; Accepted December 10, 2010; Published January 13, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This research was supported in part by the National Institute of Allergy and Infectious Diseases through the Northeast Biodefense Center (U54-
AI057158-Lipkin, sub-award to MRM), and grants R56 AI089062 (MRM) and R01 AI075099 (CMR), the National Cancer Institute (grant R01 CA057973, CMR), the
Greenberg Medical Research Institute and by the Irma T. Hirschl/Monique Weill-Caulier Trust (MRM). The research was also supported in part by the National Basic
Research Program of China (grant 2009CB522504, ZY) and the Intramural Research Program of the NIH, NIAID. The content is solely the responsibility of the
authors and does not necessarily represent the official views of any of the funding sources. Moreover, the funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: macdonm@rockefeller.edu
¤ Current address: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville,
Maryland, United States of America.
Introduction
The Flavivirus, Pestivirus and Hepacivirus genera of the Flaviviridae
family each include important human and/or animal pathogens
[1]. A major human pathogen hepatitis C virus (HCV) is a
member of the Hepacivirus genus, while Pestiviruses bovine viral
diarrhea (BVDV), border disease and classical swine fever viruses
each have significant economic consequences in the livestock
industry. Within the Flaviviridae family, members of the Flavivirus
genus, which includes over 50 viral species, have perhaps the most
significant impact on human health [2,3]. Viruses in this genus,
including yellow fever (YF), dengue (DEN), West Nile (WN),
Japanese encephalitis (JE) and tick-borne encephalitis (TBE)
viruses, contribute to staggering numbers of human infections
and significant death rates across the globe. Viruses in this genus
are usually transmitted via arthropod vectors and as such human
infection depends on climate and geographical factors affecting the
ranges of the transmitting arthropod and the likelihood of
arthropod-human contact. Rising global temperatures, increased
human population densities, human movement and increased
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numbers of epidemics in new geographical locations; this trend is
likely to continue.
While successful vaccines have been developed for prevention of
YFV, JEV and TBEV infection, none are available for other
pathogenic flaviviruses. Efforts to create and implement such
vaccines have been hampered by the presence of multiple
serotypes (DEN), the large geographical areas involved, and the
sporadic nature of infection [4,5]. Even for vaccine-preventable
flavivirus infections, the cost associated with immunizing all at-risk
people is enormous. Moreover, there are currently no drugs
available for the specific treatment of any flaviviral disease. While
several viral proteins are attractive targets for the development of
small molecule inhibitors, the potential for rapid evolution of the
flavivirus RNA genome suggests that resistance may be a
significant problem. Disrupting critical interactions of viral
proteins with host factors, or inducing expression of host proteins
able to inhibit viral replication, are alternative approaches to
developing effective anti-flaviviral therapies, and may limit the
emergence of escape mutants. Unfortunately our understanding of
host factor involvement in promoting or inhibiting flaviviral
replication remains incomplete.
Members of the Flavivirus genus share a common genome
organization and replication strategy [1]. After virion entry and
fusion of the viral and host membranes within the endosome, the
,11,000 nt viral positive sense genomic RNA is translated in
association with host cell membranes to form a single polyprotein
which is co- and post-translationally cleaved by both host and viral
proteases. The structural proteins, C, prM and E, are located in
the N-terminal region of the polyprotein, followed by the
nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B
and NS5. After appropriate cleavage and assembly of replication
complexes, the genomic RNA is replicated by NS5, the viral RNA-
dependent RNA polymerase, in association with other viral
nonstructural and host proteins to generate new progeny genomes.
Virion morphogenesis then follows via encapsidation and budding
into the ER lumen. Virions mature during transport through the
secretory pathway and are released into the extracellular milieu via
exocytosis.
Given the common replication strategy of the Flavivirus genus
members, different species may exploit or be susceptible to many
of the same host factors or environmental conditions. We
hypothesized that identification of a cellular antiviral factor with
activity against one flavivirus species may provide information on
targets for broad-spectrum therapeutics. In order to identify
antiviral cellular factors active against YFV, we conducted an
iterative screen of a cDNA library from interferon-a treated cells.
We identified DNAJC14, an Hsp40 family member, as able to
mediate protection from YFV-induced cell death. Further studies
demonstrate that DNAJC14 is recruited to YFV replication
complexes and that its overexpression inhibits viral RNA
accumulation. The C-terminus of DNAJC14, which mediates its
multimerization, is required for antiviral activity. Furthermore, we
found that silencing of endogenous DNAJC14 inhibits YFV
replication. Overall our findings suggest that DNAJC14 plays an
important role in regulating YFV replication complex assembly.
Materials and Methods
Plasmids
Retroviral vectors pV1, pV1-GFP, pTrip-EGFP and pTrip-
TagRFP have been described [6,7,8,9]. Derivatives were generated
using standard methods; all polymerase chain reaction (PCR)
generated sequences were verified by sequencing and primer
sequences are available upon request. Derivatives of pV1 were
constructed to express human DNAJC14 (hDNAJC14) and mutants,
each containing a carboxyl-terminal myc tag; the myc tag
(EQKLISEEDL) was introduced during PCR by inclusion of myc-
encoding nucleotide sequences in the antisense primers. DNAJC14-
or truncation mutant-encoding DNA was amplified, using the
Expand Long Template PCR System (Roche), from hDNAJC14
cDNA plasmid (Open Biosystems), and after digestion with SfiI was
cloned into similarly digested pV1. Plasmid pV1-hDNAJC14-FL
encodes full-length hDNAJC14 (amino acids 1–702) with a carboxyl-
terminal myc tag. The human N-terminal truncation mutant (NT1)
corresponding to the truncated hamster cDNA isolated in the screen
starts from the amino acid corresponding to residue 305 of
hDNAJC14, and was designed to have the identical amino terminus
as the hamster sequence (305MVQFLSQS—); the corresponding
human wildtype sequence has a phenylalanine residue at position
306. Additional mutants generated include NT2: 250AGFWWLIE—;
NT3: 291MGVWTGRL—; NT4: 320FTRFLKLL—; NT5:
349LVGLGDRL— and as necessary contained an extra methionine
residuefortranslationinitiation.C-terminaltruncatedmutantsend at
the following amino acids prior to the myc epitope tag: CT1: —
HISFGSRI625; CT2: —DLKEAMNT534;C T 3 :— E E V A R L L T 433;
CT4: —RFLVGLGD354; CT5: —AEELCQLG248.T h eN T 5 C T 1
mutant contains both the NT5 and CT1 truncations.Point mutations
were introduced using site directed mutagenesis with the appropriate
oligos by standard techniques.
Plasmids pTrip-EGFP-hDNAJC14-NT5 and pTrip-RFP-
hDNAJC14-FL or pTrip-RFP-hDNAJC14-NT1 were generated
by PCR amplification of the NT5, full-length (FL) or NT1
hDNAJC14 sequences. After BsrG1 and XhoI digestion the
sequences were ligated into similarly digested pTRIP-EGFP or
pTRIP-TagRFP. These plasmids express hDNAJC14 (or mutants)
fused in frame to the C-terminus of EGFP or RFP. To generate a
doxycycline-inducible cell line expressing hDNAJC14-NT5, se-
quences encoding NT5 were generated by PCR and were inserted
into pcDNA4/TO/myc-His B (Invitrogen) via HindIII and XbaI
digestion to generate pcDNA4/TO/hDNAJC14-NT5. Plasmid
Author Summary
Viruses in the Flavivirus genus are transmitted by
arthropods and cause significant disease burden across
the globe. We undertook a screening approach to select
for and identify host factors that provide resistance to
death caused by infection with the mosquito-transmitted
Flavivirus, yellow fever virus (YFV). We identified the host
factor DNAJC14, an Hsp40 chaperone protein family
member, as able to inhibit replication of the vaccine strain
of YFV, and the virulent parental Asibi strain. We found
that DNAJC14 also inhibits several other members of the
Flavivirus genus, including Kunjin and the tick-borne
Langat virus. Moreover, the Hepacivirus hepatitis C virus
is also inhibited, suggesting a role for DNAJC14 in
modulating the replication of all three genera of the
Flaviviridae family. By probing the mechanism of the YFV
inhibitory process, we determined that DNAJC14 inhibits
at a post entry step, and most likely prevents the
formation of functional replication complexes. We deter-
mined that DNAJC14 is required for YFV replication and
that expression of inappropriately high levels of this
protein results in a disruption of a process critical for viral
RNA replication. Understanding how host factors inhibit or
contribute to Flavivirus replication steps may identify new
targets for antiviral drug development.
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amino acids 1 to 252 of human zinc-finger antiviral protein [10],
generated by PCR, as an in frame fusion with the carboxyl
terminus of RFP in the pTrip-TagRFP vector.
Plasmids pFlag-HCV-NS2-3-WT or pFlag-HCV-NS2-3-
H171A were described previously [11] and express Flag-tagged
HCV NS2-3181 or the inactive H171A mutant form of the NS2
protease, respectively. Plasmids pFlag-YF-NS2-3(181)-WT or
pFlag-YF-NS2-3(181)-S138A were generated by amplification of
YFV NS2-3 fragments from plasmids pACNR-YF17D [12] and
pET-BS(+)/Sig2A-5356-R2107/2506E, S1622A [13], respectively,
and cloning the KpnI/XhoI digested products into similarly
digested pcDNA3.1. The sense primer contained appropriate
sequences to encode a Flag epitope tag on the N-termini of the
respective proteins. The plasmids express Flag-tagged YFV NS2-
3181 or the inactive S138A form of the NS3 protease, respectively.
Plasmids pACNR-FLYF17Dx [12] and pACNR-FLYF17Da
[14] contain the sequences of YFV 17D downstream of the SP6
promoter with XhoI and AflII linearization sites, respectively.
Plasmid pACNR-FLYF-Asibi (the details of which will be
described in another paper) contains the sequences of YFV Asibi
downstream of the SP6 promoter.
Plasmid pYF17D(59C25Venus2AUbi) was constructed by
inserting Venus, a variant of yellow fluorescent protein (YFP),
into the YFV 17D open reading frame (ORF) using standard
molecular techniques. All generated PCR products and plasmids
were verified by restriction digests and by sequencing (primers
available upon request). First, the Venus cassette was amplified
from plasmid Venus/pCS2 (kindly provided by Dr. Atsushi
Miyawaki) and cloned in frame after the first 25 amino acids of
the YFV Capsid in pNEB193/YF59 [15] using the SacI and AgeI
sites. Next, the foot-and-mouth disease virus (FMDV) 2A
peptide, which mediates cleavage following its own carboxy-
terminus, and a ubiquitin (Ubi) monomer were amplified from
pTM3-HCV-Ubi-NS5B (C. Lin and C.M. Rice, unpublished)
and inserted downstream of Venus in pNEB193/YF59 by
assembly PCR. YFV 17D amino acids 1–514, containing silent
mutations in sequences encoding the first 25 amino acids to avoid
recombination, were similarly assembled downstream of FMDV
2A in pNEB193/YF59. Finally, to generate pYF17D(59C25Ve-
nus2AUbi), Venus and YFV 17D sequences were removed from
pNEB193/YF59 using SrfI and NsiI and cloned into pCC1-
YF17D [16], which contains the entire YFV genome. Thus in
pYF17D(59C25Venus2AUbi), the Venus/2AUbi cassette is
inserted in frame after the first 25 amino acids of Capsid,
followed by the complete YFV polyprotein. The presence of
FMDV 2A and Ubi downstream of Venus ensures complete
cleavage from the YFV polyprotein, thereby ensuring the
authentic YFV amino terminus. This strategy has the potential
advantage of allowing expression of foreign inserts without
disrupting the YFV 17D polyprotein, which may have unpre-
dictable deleterious effects on replication.
YFV replicon plasmids pYF-R.luc2A-RP and pYF-luc-IRES-
RP-DDD [17] were kindly provided by Richard J. Kuhn (Purdue
University). Plasmid pYF-R.luc2A-RP-DDD (expressing a poly-
merase defective YFV luciferase-expressing replicon) was con-
structed by swapping the NdeI/XhoI fragment from pYF-luc-
IRES-RP-DDD into pYF-R.luc2A-RP.
Cell lines
All cell lines were maintained at 37uC in humidified chambers
containing 5% CO2. SW13 (human adrenal carcinoma) cells were
cultured in Minimum Essential Medium (MEM) Alpha Medium
(MEMa, Invitrogen) supplemented with 10% fetal bovine serum
(FBS, Invitrogen). Huh7.5 cells [18] were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Invitrogen) supplemented with
nonessential amino acids (Invitrogen) and 10% FBS. HEK293T
and Vero cells were cultured in DMEM supplemented with 10%
FBS. T-REx-293-LacZ cells inducibly expressing myc-tagged
LacZ were previously described [19]. T-REx-293-NT5 cells
inducibly expressing hDNAJC14-NT5 were obtained by transfec-
tion of T-REx-293 cells with pcDNA4/TO/hDNAJC14-NT5 and
selection in medium containing zeocin. The selected bulk
population was then cultured in DMEM supplemented with
10% FBS, 5 mg/ml blasticidin, and 0.5 mg/ml zeocin. For
induction, doxycycline was added to a final concentration of
1 mg/ml. BHK-J cells, a previously described [20] line of BHK-21
hamster kidney cells were cultured in MEM supplemented with
7.5% FBS and BHK/NZAP-Zeo cells [21] were maintained in the
same medium with the addition of 200 mg/ml zeocin.
Antibodies
Anti-Myc mouse monoclonal antibody 9E10 (ATCC CRL1792
hybridoma) was used in Western and immunofluorescence or
immunoprecipitation at 2.5 and 16 mg/ml, respectively. Anti-Flag
antibody (Sigma M2 mouse monoclonal) was used in Western
analysis at 1:1000 dilution. Yellow fever NS3 rabbit polyclonal
antiserum was previously described [22] and utilized at 1:5000
dilution for Western analysis, and 1:500 for immunofluorescence.
Rabbit polyclonal anti-GFP antiserum was generated as described
[23] and utilized at 1:20,000 dilution in Western and 1:1000 in
immunoprecipitation. Mouse monoclonal anti-calnexin antibody
(BD Biosciences, 610523) was used in Western and immunoflu-
orescence at 1:250 and 1:50 dilution, respectively. Mouse
monoclonal anti-actin (Sigma, A5441) antibodies were utilized in
Western analyses at 1:5000 dilution. Rabbit polyclonal anti-
DNAJC14 antibody (Sigma, HPA017653) was used in Western
and immunofluorescence at 1:2000 and 1:200 dilution, respec-
tively. Mouse monoclonal anti-double stranded RNA (dsRNA) J2
antibody (English & Scientific Consulting, Bt. Szira ´k, Hungary),
kindly provided by Dr. Elena Frolova (University of Alabama at
Birmingham), was used at 1:200 dilution. Alexa Fluor 488 donkey
anti-mouse IgG (A-212020) and Alexa Fluor 594 goat anti-rabbit
IgG (A-11012, Invitrogen) were utilized in immunofluorescence at
1:000 dilution. YF 17D neutralizing mouse monoclonal antibody
8A3 [24] ascitic fluid was kindly provided by Jack Schlesinger
(University of Rochester). A dilution of 1:100 was found to
efficiently neutralize up to 10
5 pfu of YFV (data not shown). HRP-
conjugated secondary anti-mouse (Jackson ImmunoResearch,
115-035-146) and anti-rabbit (Pierce, 31462) IgG antibodies were
utilized at 1:20,000 dilution. Normal rabbit IgG used in
immunoprecipitations was from Santa Cruz Biotechnology, Inc.
Viruses, virus titration and electroporation
YFV stocks were generated by electroporation of BHK-J cells as
previously described [25] with in vitro transcribed YFV RNA.
Plasmids pACNR-FLYF17Dx [12], pYF17D(59C25Venus2AUbi),
and pACNR-FL-YF-Asibi were used for generation of YF 17D,
YFV-Venus or YF Asibi, respectively. All work with YF Asibi was
conducted under Biosafety level 3 containment conditions. Virus
stocks and samples were titered by infection of BHK-J cells with
10-fold serial dilutions in MEM with 2% FCS. Two hundred mlo f
diluted virus was added to each 35 mm well and after 1 h of
infection the well was overlaid with 0.6% agarose in MEM
supplemented with 2% FBS. Plaques were enumerated by crystal
violet staining after 72 h. For YFV infections, multiplicity of
infection (moi) was based on titers obtained on BHK-J cells.
DNAJC14 Modulates Flavivirus Replication
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expressing Gaussia luciferase was prepared by electroporation of
Huh7.5 cells as described previously [26].
Stocks of Kunjin (derived from infectious clone FLSDX 250pro)
were propagated on Vero cells as described [27,28]. Langat (TP21
strain) was propagated on Vero cells as described [29]. Titrations
of stocks and samples were performed by focus forming assay, as
previously described [30,31]. Briefly, Vero cells were infected with
10-fold serial dilutions and after the 1 h adsorption the wells were
overlaid with 0.8% methylcellulose in DMEM containing 2%
FBS. After 4 d the monolayers were fixed with 100% methanol
and plaques were visualized by incubation with polyclonal mouse
antibody cross-reactive to Langat (hyperimmune mouse ascites
fluid, clone Russian Spring Summer Encephalitis VR79; ATCC)
or polyclonal mouse anti-West Nile virus E protein (obtained from
Dr. Robert Tesh, World Reference Center for Emerging Viruses
and Arboviruses) followed by secondary goat anti-mouse perox-
idase-labelled polymer (DAKO Envision Systems) and application
of peroxidase substrate containing 0.4 mg/ml 3,39 diaminobenzi-
dine and 0.0135% hydrogen peroxide in PBS.
To bypass entry steps, SW13 cells were electroporated
essentially as described [32] with in vitro transcribed RNA
generated from plasmid pACNR-FLYF17Da, YF-R.luc2A-RP, or
pYF-R.luc2A-RP-DDD.
Preparation of lentiviral stocks and transduction of cells
Stocks containing VSV-G pseudotyped lentiviral particles were
generated essentially as described [7] by cotransfection using
Fugene 6 (Roche) of 293T cells with plasmids encoding VSV-G,
HIV gag-pol and the lentiviral provirus plasmid at a ratio of
1:4:4 mg. Medium overlaying the cells was harvested at 48–72 h
after transfection, filtered through a 0.45 mM filter, aliquoted and
stored at 280uC. Transductions were performed by incubating
cells with the pseudoparticles in the presence of 8 mg/ml
polybrene. The tissue culture 50% infectious dose (TCID50) was
determined essentially as described [33] by titration on the TZM
HeLa cell derivative [34], which expresses b-galactosidase under
the control of the HIV LTR. Comparison of the TCID50 of a
VSV-G pseudotyped V1-GFP stock, as determined on TZM cells,
to the number of GFP-positive cells obtained after transduction of
the target cell line with the same V1-GFP stock allowed for
calculation of the appropriate TCID50 to utilize to achieve the
desired transduction efficiency. For protein expression, transduc-
tion efficiency was typically in the range of 70–95%.
Hamster cDNA library construction
A cDNA library was generated as described [7] from mRNA
isolated from a BHK-21 derivative cell line, designated BHK/
NZAP-Zeo [21], expressing the amino terminal fragment of the
rat zinc-finger antiviral protein, after treatment for 6 h with
100 U/ml Universal type I IFN (PBL Biomedical Laboratories).
Briefly, total RNA was harvested with Trizol (Invitrogen) and
mRNA isolated by oligo dT selection (Oligotex mRNA Maxi Kit,
Qiagen) according to the manufacturer’s recommendations. The
cDNA synthesis was carried using the method of the SMART
cDNA Library Construction Kit (Clontech) with the outlined
modifications [7] which utilized Superscript III (Invitrogen) for
first strand synthesis and TaqPlus Long PCR System (Stratagene)
for second strand synthesis and amplification, SfiI digestion and
size fractionation with cDNA Size Fractionation Columns
(Invitrogen). After ligation to the minimal HIV provirus V1 vector
that had been SfiI-digested, and electroporation of DH10B cells
(Invitrogen), the library was divided into two sub-libraries (L1 and
L2), each with .3,000,000 clones, for amplification. Plasmid DNA
was isolated from the amplified libraries using a Qiagen MaxiPrep
Kit, and VSV-G pseudotyped particles expressing the library
cDNAs were generated as described above. Library L1 contained
insert sizes ranging from ,400 to ,2,400 nt and was utilized for
these studies.
cDNA library screen with cyclic packaging rescue
The L1 cDNA library was screened for cDNAs able to confer
resistance to YFV 17D-mediated cell death using a previously
described iterative approach [7] and as outlined in Figure 1. SW13
cells (18 million) were transduced with the L1 library of lentiviral
particles (0.45 TCID50/cell) and two days later were challenged
with YFV 17D (moi=5). After maintenance in MEM with 2%
FBS for 7 d, the surviving Round 1 (Rd 1) cells were pooled and
expanded in growth medium. The cDNA clones present in the
surviving Rd 1 cells were rescued by transfection of cells in two
10 cm dishes with 15 mg VSV-G- and 5 mg HIV gag-pol-encoding
plasmids diluted in OptiMem containing 40 ml Lipofectamine
2000 (Invitrogen)-according to the manufacturer’s recommenda-
tions. The medium overlying the cells was collected 2 d later,
pooled, filtered through a 0.45 mM filter, aliquoted and stored at
280uC. For subsequent steps, the rescued lentiviral stocks were
treated for 2 h at room temperature with a 1:100 dilution of
mouse monoclonal 8A3 YFV neutralizing antibody prior to
transduction of naı ¨ve SW13 cells in order to prevent cell death
mediated by residual YFV in the lentiviral stock. Each rescued
stock was utilized undiluted for subsequent transductions. Two
additional rounds of transduction and challenge were performed
to generate Rd 2 and Rd 3 cells and rescued lentiviral stocks. Rd 2
was performed on ,4610
6 SW13 cells, (0.0003 R1 TC1D50/cell),
Figure 1. Selection and identification of host factors conferring
protection against YFV-induced cell death. A schematic of the
iterative selection process is shown.
doi:10.1371/journal.ppat.1001255.g001
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performed on the surviving Rd 2 cells in three 35 mm dishes,
using Lipofectamine 2000-mediated transfection as described
above (13 ml reagent, with 3 mg VSV-G- and 1 mg HIV gag-pol-
encoding plasmids per dish). Rd 3 was performed on ,2610
6
SW13 cells (0.07 R2 TC1D50/cell) and a YFV 17D challenge
(moi=1) 2 days later. A large number of cells survived the
challenge compared to cells transduced with V1-GFP and
challenged in parallel (see Figure 2A) and these Rd 3 cells were
expanded for further testing. Rescue was performed as in Rd 2. A
repeat experiment using the same Rd 2 rescued lentiviral stock
gave similar results and an additional selection round using
particles rescued from the Rd 3 cells also yielded many surviving
Rd 4 cells (not shown).
Identification of the cDNA conferring resistance to YFV
The predominant cDNA present in the Rd 3 cells was isolated
by PCR. Rd 3 cellular DNA was isolated using the DNeasy Blood
and Tissue Kit (Qiagen) and amplified using the Expand High
Fidelity PCR System (Roche) and primers flanking the cDNA
insert in the V1 vector (59-GATTGTAACGAGGATTGTG-
GAACTTCTGGG-39 and 59-GATCCACAGATCAAGGATA-
TCTTGTCTTCTTTGGG-39). The PCR product was digested
with SfiI, recloned into the V1 vector and sequenced using the
above primers, as well as with primers designed to bind within the
DNAJC14 sequence (5-TTGAAGCCACAGCATCC-39 and
AAGTCTACAGCTGCTCGAG-39). Blast analysis demonstrated
high homology with murine and human DNAJC14 with the
cDNA insert predicted to express an amino-terminally truncated
form of the protein. The nucleotide sequence of the truncated
hamster DNAJC14 cDNA was submitted to GenBank
(BankIt1399336 DNAJC14 HQ415606).
Immunoprecipitation
To demonstrate DNAJC14 self interaction, HEK293T cells
were seeded 16 h before transfection onto 60 or 100 mm tissue
culture dishes at a density of 1.6610
6 or 4610
6 cells, respectively.
The cells were co-transfected using Fugene 6 (Roche) with 2
(60 mm dish) or 4 (100 mm dish) mg each of pTrip-EGFP-
hDNAJC14-NT5 and pV1-hDNAJC14-FL or mutants. Forty-
eight hours post transfection, cells were scraped into ice-cold PBS
and solublized with lysis buffer (10 mM HEPES, pH 7.5, 150 mM
KCl, 3 mM MgCl2, 0.5% NP-40, 16Proteinase inhibitor cocktail
(Roche)), using 300 or 600 ml for 60 or 100 mm dishes,
respectively. After disruption by passing through a 27G needle 5
times and clarification by centrifugation at 15,0006g for 10 min at
4uC, 300 ml of the soluble fraction was incubated overnight at 4uC
with anti-myc, anti-GFP or control antibody. Pre-equilibrated
protein A/G-agarose beads (Santa Cruz) were then added, and
after 2 h of incubation, were collected by centrifugation and then
washed four times with 600 ml washing buffer (10 mM HEPES,
pH 7.5, 150 mM KCl, 3 mM MgCl2, 0.05% NP-40). The bound
proteins were eluted by boiling in sodium dodecyl sulfate (SDS)
sample buffer and were subjected to Western analysis.
To demonstrate the NS3-DNAJC14 interaction, SW13 cells
were transduced with lentivirus expressing the myc tagged CT1
hDNAJC14 mutant and 2 d later were infected with YFV
(moi=1). After 2 d the cells were harvested and immunoprecip-
itation performed as described above except that the lysis and
wash buffer contained 1% NP-40.
Western blot analysis
Cells were directly lysed with 26SDS loading buffer (100 mM
Tris-Cl pH 6.8, 20% Glycerol, 4% SDS, 3% b-mercaptoethanol,
0.02% bromophenol blue) and boiled for 5 min. Proteins were
separated by SDS-polyacrylamide gel electrophoresis (PAGE) and
transferred to a Hybond ECL Nitrocellulose Membrane (GE
Healthcare Life Sciences). The membrane was incubated in
blocking buffer (PBS, 0.05% Tween 20, 5% dried milk) for 2 h,
and then incubated with primary antibody diluted in blocking
buffer at 4uC overnight. The membrane was washed 3 times in
PBS supplemented with 0.05% Tween 20 and incubated for 2 h at
room temperature with HRP-conjugated secondary antibody.
After 3 washes, the membrane was visualized by ECL Supersignal
West Pico (or Femto) Chemiluminescent substrate (Thermo
scientific).
Immunofluorescence and confocal microscopy
Cells were fixed with 4% formaldehyde in PBS and permea-
blized with 0.2% Triton X-100 in PBS for 5 min at room
temperature. After being washed with PBS, samples were then
blocked and incubated overnight with primary antibody in 3%
Figure 2. DNAJC14 confers resistance to YFV-induced cell
death. (A) Photographs 7 d after YFV challenge (moi=1) of SW13 cells
transduced with Round 3 of the selected lentiviral cDNA constructs
compared to cells transduced with V1-GFP vector control. (B) The cells
transduced with the Round 3 lentivirus pool and surviving YFV infection
(Rd 3) were expanded and reinfected with YFV at the indicated moi.
Crystal violet staining was performed 3 d later. Cells transduced with
vector alone serve as a control (V1-GFP). (C) DNA was isolated from
naı ¨ve SW13 or Round 3 (Rd 3) cells, and the lentiviral insert amplified by
PCR. The major band was identified as encoding a truncated hamster
DNAJC14. Sizes of the DNA markers (kb) are indicated to the left. (D) A
schematic of human DNAJC14 is shown, with the putative transmem-
brane (TM) domains (gray), J domain (red) with conserved HPD
sequence, zinc finger motifs (blue) and Jiv90 domain (orange) indicated.
A schematic of the isolated hamster clone, showing homology to amino
acids 305 to 702 of human DNAJC14, is shown below.
doi:10.1371/journal.ppat.1001255.g002
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incubated at 37uC for 1 h with Alex488- or Alex594-conjugated
secondary antibody. Coverslips were finally mounted with Mowiol
Mounting Media [0.1 M Tris-HCl, pH 8.5, 25% glycerol, 10%
Mowiol 4–88 (Calbiochem 475904)] and observed by Leica
LSM510 confocal laser with a 1006NA 1.3 oil immersion
objective. Images were captured using the LSM software and
processed using ImageJ.
Flow cytometry
Cells were harvested by trypsinization, resuspended in PBS with
1% BSA, and then fixed in 2% formaldehyde in PBS. Samples
were analyzed for expression of RFP and Venus using a BD LSR
II flow cytometer, analyzing 10,000 events per sample. Data were
processed using the FlowJo software.
Luciferase assays
For the luciferase activity assay, transduced and infected
Huh7.5 cells were washed twice with PBS and lysed with 16
Passive Lysis Buffer (Promega) according to the manufacture’s
recommendations. Luciferase activity was measured using the
Renilla Luciferase Assay system (Promega) using a Lumat LB9507
Luminometer (Berthold).
RNAi-mediated silencing and quantitative RT-PCR
Triplicate wells of SW13 cells transduced with V1-GFP control
or DNAJC14-expressing lentiviruses were seeded in 24 well plates
at 1610
5 cells per well in the presence of 60 nM Stealth RNAi
siRNA Negative Control Med GC (12935-300) or DNAJC14-
targeting Stealth siRNA (CCGAGGAACUAUGUCAACUUG-
GACA) and Lipofectamine RNAiMAX (Invitrogen) according to
the manufacturer’s reverse transfection protocol. The siRNA
transfection was repeated 2 d later, using forward transfection with
60 nM siRNA. After an additional 2 d incubation, the cells were
infected with YFV (moi=5) and 24 h later the medium was
collected for virus titration. For each condition, cells from one of
the triplicate wells were harvested for Western blot analysis, while
the remaining 2 wells were pooled for RNA harvest. RNA was
purified using the RNeasy minikit (Qiagen) and each sample was
reverse transcribed in triplicate using random primers and the
Superscript III first strand synthesis kit (Invitrogen). Quantitative
PCR was performed using the QuantiTect SYBR Green PCR Kit
(Qiagen) and a LightCycler 480 (Roche) for detection as previously
described [35]. Qiagen QuantiTect primers (QT00197043) were
used for DNAJC14 amplification; levels were normalized to those
of GAPDH, using a GAPDH primer set (sense: CCCACTCCTC-
CACCTTTGAC, antisense: CATACCAGGAAATGAGCTT-
GACAA) as described [36].
Results
Truncated hamster DNAJC14 inhibits YFV-mediated cell
death
To identify cellular factors with antiviral activity against
flaviviruses, we initiated a screen for host proteins that could
inhibit cell death caused by YFV infection. We reasoned that a
cDNA expression library generated from cells treated with
interferon (IFN)-a to increase expression of antiviral factors would
represent both IFN induced and constitutively expressed factors,
some of which might have a protective effect against YFV. For this
study, we utilized a cDNA library that we had generated (for other
unrelated studies) from a BHK-21 cell derivative previously shown
to develop dramatic resistance to Sindbis virus infection upon
treatment with IFN [21]. Although we had some concerns
regarding possible species incompatibilities for the function of
hamster proteins in cells of other species, we thought it likely that
factors influencing YFV, which has conserved replication
strategies in both vertebrate and invertebrate cells, would function
in a broad range of cells. We transduced YFV-susceptible human
SW13 cells with the expression library, challenged these cells with
YFV (vaccine strain 17D), and identified the cDNA(s) expressed in
cells that survived the infection. During initial screens, we
encountered several challenges, including difficulty cloning out
rare surviving cells, and the presence of multiple library integrants.
In order to overcome these obstacles, we expressed the cDNA
library using a lentiviral vector (V1) in cells that are amenable to
repackaging, as has been previously described [7]. Transfection of
cells surviving the YFV challenge with helper plasmids expressing
HIV gag-pol and an envelope glycoprotein (VSV-G) allows
packaging of the lentiviral genomes, generating a lentivirus stock
enriched for genes that confer a selective advantage (Figure 1).
This approach obviates the need to clone individual cells, and
allows iterative cycles of library transduction, YFV challenge, and
rescue of sequences conferring survival. A YFV neutralization step
of the selected, rescued lentiviral particles was used to prevent cell
death mediated by residual virus during transduction of the naı ¨ve
SW13 cells. After multiple rounds, the pool of cDNA-expressing
lentiviruses will have markedly reduced complexity and active
cDNA clones will be highly enriched.
After two rounds of selection, transduction of SW13 cells with
the enriched library of lentiviral constructs resulted in extensive
resistance to YFV-induced cell killing (Figure 2A). These ‘‘Round
3’’ (Rd 3) cells were expanded, retested for their susceptibility to
YFV-induced cytopathicity and found to be resistant at several
multiplicities of infection (moi, Figure 2B). DNA was harvested
from the Rd 3 cells, and the cDNA inserts were amplified using
primers specific for the V1 vector (Figure 2C). The single major
PCR product (,2.5 kb) was cloned, sequenced and found by
BLAST analysis to show high homology to a murine (as well as
human) Hsp40 family member, DNAJC14. The cDNA was
predicted to express an N-terminally truncated version of the
protein, which, based on the human sequence, lacked the first 304
amino acids of the 702 amino acid protein. DNAJC14 and the
truncated hamster clone are shown schematically in Figure 2D.
To test whether the DNAJC14 sequence obtained by PCR
could confer resistance to YFV-mediated cell death in naı ¨ve cells,
the PCR product was cloned back into the V1 lentiviral vector.
Five individual clones (designated 1-1, 1-2, 1-3, 1-4, and 1-5) were
packaged and the VSV-G pseudotyped lentiviral particles were
used to transduce naı ¨ve SW13 cells, which were challenged with
YFV. Clone 1-1 was unable to confer resistance to YFV-mediated
cell death, while each of the remaining four clones resulted in
protection (data not shown). Sequencing of clones 1-1 and 1-2
indicated that both encoded a 398 amino acid protein (equivalent
to human DNAJC14 aa 305–702) but clone 1-1 encoded a leucine
to proline mutation at position 466, likely introduced during PCR
amplification. This leucine is within the highly conserved J domain
and is conserved amongst human, chimp, dog, cow, mouse and rat
sequences. We conclude from these studies that expression of
amino acids 305–702 of hamster DNAJC14 is able to confer
resistance to YFV-mediated cell death.
Because our screen used cDNA from IFN-a-treated cells, we
tested whether interferon treatment of SW13 cells results in
upregulation of DNAJC14 mRNA levels. After treatment for 8 h
with IFN-a, DNAJC14 RNA levels were quantified by real time
RT-PCR. No significant differences in DNAJC14 RNA levels
were found in cells treated with doses of IFN-a ranging from 0 to
1000 IU/ml (data not shown). Detection of eIF2a phosphorylation
DNAJC14 Modulates Flavivirus Replication
PLoS Pathogens | www.plospathogens.org 6 January 2011 | Volume 7 | Issue 1 | e1001255by Western blot demonstrated that IFN was active in these cells
(data not shown). Although we cannot exclude that the gene may
be upregulated in response to IFN-a in some cell types, DNAJC14
appears to be constitutively expressed in SW13 cells.
DNAJC14 mediates cell protection by inhibition of viral
replication
Our screen utilized protection from viral-mediated cell death as
an endpoint for the isolation of host proteins with activity against
YFV. Survival could be due to inhibition of virus replication or
prevention of activation and/or blocking of cell death pathways.
To test whether expression of DNAJC14 resulted in inhibition of
viral growth, we infected the Rd 3 cells with YFV and quantified
virus production (Figure 3A). Compared to naı ¨ve cells, YFV
propagation was markedly reduced in DNAJC14 expressing cells,
with a greater than 2 log reduction in infectious titers at 48 h, and
virus production continuing to decrease over time. In contrast,
robust replication occurred at 48 h in the naı ¨ve cells, with
infectious titers decreasing at 5 d, at which time the cells displayed
massive cytopathic effect. To determine whether the decreased
infectious titers were a result of decreased intracellular viral
replication, we performed Western blot analysis (Figure 3B) on
YFV-inoculated cells transduced with V1 vector containing the
clone 1-2, 1-3, 1-4 and 1-5 inserts. We found reduced levels of the
viral NS3 protein in the cells expressing hamster DNAJC14
compared to control cells transduced to express GFP. These
results demonstrate that truncated hamster DNAJC14 blocks YFV
infection and/or replication, which results in prolonged cell
survival.
The truncated hamster DNAJC14 isolated in our screen is
highly homologous to murine and human DNAJC14 proteins
(89% identical and 93% similar to the corresponding region of the
proteins). We therefore determined if expression of the 702 amino
acid human DNAJC14 protein, also designated dopamine
receptor interacting protein (DRIP78), could also confer protec-
tion against YFV-mediated cell death. We generated V1 lentiviral
expression constructs to for both the full-length hDNAJC14
(hDNAJC14-FL) as well as an amino terminal truncation mutant
(designated NT1) expressing amino acids 305–702 of human
DNAJC14 (hDNAJC14-NT1), which corresponds to the hamster
protein identified in our screen. A C-terminal myc epitope tag was
engineered in the constructs to allow detection of the proteins.
After packaging, the lentiviral pseudoparticles were used to
transduce SW13 cells, which were then challenged with YFV
(Figure 3C). Both the full-length and truncated versions of
DRIP78 inhibited intracellular YFV NS3 accumulation. These
studies demonstrate that the human DNAJC14 homolog is able to
inhibit YFV infection and/or replication, as well as show that the
addition of a C-terminal epitope tag does not interfere with the
inhibitory activity.
DNAJC14 is a broad-spectrum Flaviviridae family
replication modulator
Bovine DNAJC14 (also known as J-domain protein interacting
with viral protein, or Jiv) has previously been implicated in
regulation of pestivirus (BVDV) replication. Intriguingly, cyto-
pathic strains of the virus can contain insertions of DNAJC14
within their genome [37,38,39]. A portion of the Jiv protein (Jiv90)
is required for the substrate interaction and activity of the viral
autoprotease (NS2) and the subsequent establishment of replica-
tion complexes [40,41,42]. We therefore wondered how expres-
sion of DNAJC14 would affect other members of the Flavivirus
genus, as well as the Hepacivirus genus member HCV. We first
Figure 3. DNAJC14 inhibits YFV replication. (A). YFV replication is
inhibited in Round 3 (Rd 3) cells. Rd 3 or naı ¨ve cells were infected with
YFV (moi=1) and at the indicated days after infection the amount of
virus released into the medium was determined by plaque assay. A
single well was used for each cell type, with replacement of the
medium at each timepoint. (B). Hamster DNAJC14 inhibits YFV protein
expression. SW13 cells were transduced with control lentivirus (V1-GFP)
or lentivirus containing the truncated hamster DNAJC14 insert (clone 1-
2, 1-3, 1-4 and 1-5) and were infected 2 d later with YFV (moi=0.5). Cells
were analyzed by Western blot for NS3 expression 3 d after infection.
Naı ¨ve cells serve as a negative control and actin serves as a loading
control. (C). Full-length and truncated human DNAJC14 inhibit YFV
replication. SW13 cells were mock transduced (Mock) or transduced
with the indicated lentiviral vectors and 2 d later were infected with
YFV (moi=0.5) as indicated. Cells were harvested and subjected to
Western blot analysis 3 d after infection using antibodies as indicated to
the right. V1-FL expresses myc epitope tagged full-length human
DNAJC14 while V1-NT1 expresses myc tagged truncated human
DNAJC14 (aa 305–702). Naı ¨ve cells were left untransduced and
uninfected and serve as a negative control. For B and C migration of
size standards (in kDa) is indicated.
doi:10.1371/journal.ppat.1001255.g003
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strain) and the prototype virulent Asibi strain isolated from a
young Ghanaian patient in 1927 [43]. Measuring of infectious
virus production by transduced cells indicated that both the
vaccine and Asibi YFV strains were susceptible to inhibition by the
truncated or full-length hDNAJC14 (Figure 4A and B). Kunjin, a
more distantly related mosquito-borne Flavivirus genus member
(from the Japanese encephalitis serocomplex group) was also found
to be susceptible to hDNAJC14-mediated inhibition (Figure 4C).
A representative of the tick-borne encephalitis group, Langat virus,
was similarly susceptible to hDNAJC14’s inhibitory effects
(Figure 4D). It therefore seems likely that DNAJC14 broadly
affects members of the Flavivirus genus. To establish whether
hDNAJC14 also has effects on the Hepacivirus genus, we used HCV
Jc1FLAG2(p7-nsGluc2A), a cell-culture infectious virus (HCVcc)
expressing a luciferase reporter [26]. Again, both the full-length
DNAJC14 and NT1 truncation mutant, corresponding to our
isolated hamster clone, inhibited viral propagation. Taken all
together, these results suggest that DNAJC14 modulates the
replication of many or all members of the Flaviviridae family.
DNAJC14 inhibits YFV infection at a post entry step
Since DNAJC14 regulates dopamine D1 receptor transport
[44], it is possible that inhibition of YFV is the result of disrupting
the transport of a cell surface receptor(s) utilized by the virus. We
introduced the YFV genomic RNA into cells by electroporation in
Figure 4. DNAJC14 inhibits multiple members of the Flaviviridae family. SW13 (A, B) or Huh7.5 (C–E) cells were seeded in equal numbers into
plates and transduced with V1 vector expressing GFP (GFP, filled circles), V1 vector expressing full-length human DNAJC14 (FL, open circles) or V1
vector expressing truncated (aa 305–702) human DNAJC14 (NT1, triangles). After 2 days, the cells were challenged (moi=5) with YFV 17D (A), YFV
Asibi (B), Kunjin virus (C), Langat virus (D) or were challenged (moi=0.1) with HCV Jc1FLAG2/p7-nsGluc2A. The medium (A–D) or cells (E) were
harvested at the indicated times for quantification of virus replication. For A and B, a single separate well was utilized for each time point, and virion
production was enumerated by plaque assay. In both cases, there were fewer than 100 plaque-forming units at 12 h post infection. The dashed line
indicates the sensitivity of the plaque assay. Pfu, plaque forming units. For C and D, duplicate wells were infected and the medium was harvested and
replaced at each timepoint. Virion production since the prior time point was enumerated by focus forming assay as described in Materials and
Methods. Data points represent the mean titer; error bars indicate the range. Similar results were obtained in an independent experiment for both
Kunjin and Langat viruses. FFU, focus forming units. For E, cells were harvested at the indicated times after infection for measurement of luciferase
activity as described in Materials and Methods. Data points represent mean values obtained from triplicate wells; error bars indicate the standard
deviation. RLU, relative light units.
doi:10.1371/journal.ppat.1001255.g004
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affected by DNAJC14. We found that DNAJC14 was still able to
mediate inhibition of YFV protein expression when entry steps are
bypassed; infectious virion production was also reduced (Figure 5A
and B). The reduced protein levels and virion production might be
due to decreased translation, RNA replication, assembly and/or
egress. Using a YFV replicon (Figure 5C) expressing luciferase in
place of the structural proteins [17], we tested whether DNAJC14
results in reduced expression of viral protein. The results
(Figure 5D, wildtype replicon) demonstrate that YFV translation
levels are reduced at later time points in the DNAJC14-expressing
cells. Since the replicon does not express the structural proteins
and is incapable of spread, the results suggest that DNAJC14-
mediated inhibition can occur at a step after entry and prior to
assembly, egress and spread. Interestingly, luciferase expression at
early time points after electroporation was similar in the control
(V1-GFP) and DNAJC14-expressing cells, suggesting that genome
translation is not inhibited by DNAJC14. At later times (after 8 h)
increased luciferase activity was detected in the control cells,
suggesting that new RNA had been synthesized for translation.
Use of a replicon containing a mutation abolishing RNA-
dependent RNA polymerase activity (DDD) demonstrates that
translation of the genomic RNA is similar in DNAJC14
overexpressing and control cells. Taken together the results
indicate that a step after entry and translation and before assembly
and egress is affected by DNAJC14.
Mutagenesis of DNAJC14 implicates the J domain and
C-terminus in YFV inhibition
To ascertain determinants of DNAJC14 inhibitory function, we
generated deletion and point mutants and tested their ability to
inhibit YFV infection. A schematic of the deletion mutants is
shown in Figure 6A. Expression levels, as determined by Western
blot detecting the C-terminal myc tag on each of the constructs,
were variable (Figure 6B), although immunofluorescence analysis
verified almost 100% percent transduction efficiency for each of
the mutants (data not shown). DNAJC14 has been proposed to
reside in the ER membrane with both its N and C termini located
within the cytoplasm [44]. This predicted topology was based on
the interaction of DNAJC14 with the C terminus of the dopamine
D1 receptor, as well as on DNAJC14 hydrophobicity plots and the
absence of a signal peptide. Topology prediction programs suggest
three potential regions that may serve as transmembrane (TM)
domains. The truncated hamster mutant identified in our screen
(NT1) contains an amino terminal deletion and is predicted to
have one TM domain. Of the N terminal deletion mutants, NT3,
NT4 and NT5 (lacking one, two or all three potential TM
domains) exhibited similar antiviral activity to the full-length
protein, while NT1 (lacking two) and NT2 (containing all three
TM domains) exhibited the most potent activity (Figure 6C). Thus
while the most inhibitory mutants contained at least one putative
TM domain, the presence of a TM domain is not strictly required
for inhibition. The C terminal deletion series were uninformative
with respect to the role of the TM domains, since deletion of the C
terminal 77 amino acids of DNAJC14 (mutant CT1), and various
further deletions (mutants CT2, CT3, CT4, and CT5, which lacks
all 3 TM domains) all resulted in a protein devoid of antiviral
activity (Figure 6C). This suggests the carboxyl terminal 77 amino
acids of DNAJC14 are required for antiviral activity. Although
mutants CT3, CT4, and CT5 all contained deletions of the J
domain, they also were not informative as to the role of the J
domain in antiviral activity, since they also lacked the important C
terminal domain.
We utilized the NT5 mutant, which has robust expression and
inhibitory activity equivalent to wildtype hDNAJC14, as the
backbone to test several point mutations for their affect on YFV
inhibition (Figure 6B, C). Our initial hamster clone 1-1 construct
contained a presumed PCR-induced mutation at leucine 466 (to
proline) within the J domain and was unable to confer resistance to
YFV (not shown). We tested the L466P mutation in the context of
hDNAJC14-NT5 and found that it abrogated the antiviral activity
against YFV, suggesting a role for the J domain in the inhibitory
process. Within the J domain, the conserved HPD motif is
important for accelerating the ATPase activity of Hsp70 [45] and
mutation of this motif (mutant H471Q) resulted in a noninhibitory
protein. Studies on the interaction of rat DNAJC14 with the
dopamine receptor [44] implicate the zinc fingers within the Jiv90
domain as important to the dopamine receptor-DNAJC14
interaction; mutation of cysteine 536 (537 in human DNAJC14,
Figure 6), to serine abolished the DNAJC14-dopamine receptor
interaction. We therefore generated mutations in two of the
conserved Jiv90 cysteine residues, predicted to be involved in zinc
coordination. Interestingly, mutants C537S and C559S could still
inhibit YFV infection. We also mutated two residues (Y617A,
I619A) that are required for maximal bovine Jiv90-mediated
stimulation of BVDV NS2-3 cleavage [40]. Interestingly, these two
mutants also displayed potent anti-YFV activity. Taken all
together, the results suggest that the J domain and C-terminal
domain are important for DNAJC14’s inhibitory effects on YFV.
Both the DNAJC14 determinants important for modulation of
pestivirus and flavivirus replication, as well as the result of
DNAJC14 overexpression differ for viruses in these two Flaviviridae
genera.
The DNAJC14 carboxyl terminus mediates
self-interaction and is required for antiviral activity
Hsp40 family members are categorized into three classes
[45,46,47]. Type I proteins contain the J domain at the N
terminus followed by a glycine/phenylalanine rich region, four
zinc finger motifs and a peptide binding fragment, with a C-
terminal dimerization domain. Type II proteins contain an amino
terminal J domain, and C-terminal peptide binding fragment, but
lack the zinc-finger motifs, while Type III proteins are variable,
with the J domain localized anywhere in the protein. DNAJC14
would thus be categorized as a Type III Hsp40, although the
presence of two zinc-finger motifs downstream of the J domain
suggests some similarities to the Type I members. Structural and
functional analyses of several Type I and Type II Hsp40 members
[45,46] demonstrate that the C-terminal domains mediate
dimerization. We therefore investigated whether DNAJC14 was
capable of self-interaction. Using the NT5 mutant, which contains
the C-terminal region, we tested its ability to interact with itself
and with full-length DNAJC14. SW13 cells were cotransfected
with plasmids expressing GFP and myc tagged DNAJC14 proteins
and immunoprecipitations were performed using anti-myc anti-
bodies. GFP-tagged NT5 co-purified with myc-tagged DNAJC14
or NT5 during myc-mediated immunoprecipitation, demonstrat-
ing self-interaction (Figure 7A). The NT5 self-interaction was
verified by the reciprocal immunoprecipitation using anti-GFP
antibodies (Figure 7B, left panel). However, mutant NT5 lacking
the C-terminal 77 amino acids (NT5CT1) failed to co-purify in the
immunoprecipitation (Figure 7B, right panel). Thus, similar to the
Type I Hsp40 members, DNAJC14 multimerizes, and the self-
interaction is mediated by the C-terminal 77 amino acids. Since
the CT1 mutant also fails to inhibit YFV, it is possible that
multimerization (likely dimerization) is important for DNAJC14’s
antiviral activity.
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cleavage
DNAJC14 is a required cofactor for the BVDV NS2 protease,
which mediates autoproteolytic cleavage of NS2-3 as a necessary
prerequisite for RNA replication [40]. Overexpression of
DNAJC14 enhances cleavage at the 2/3 site, RNA replication
Figure 6. Mutagenesis of DNAJC14. (A) A schematic of DNAJC14 is
shown with the truncation mutants indicated below. Arrows above the
schematic indicate the location of point mutants engineered in the NT5
truncation mutant backbone. Each mutant contained a C-terminal myc
epitope tag, indicated in green. (B and C) SW13 cells were transduced
with lentivirus expressing the indicated mutants and 2 d later were
challenged with YFV (moi=5). Cells and media were harvested 1 d later.
V, control V1 lentivirus; FL, lentivirus expressing full-length hDNAJC14;
WT, the NT5 truncation mutant without any point mutations. (B)
Western blot analysis was performed on equal volumes of the cell
extracts using anti-myc antibody to detect the tagged DNAJC14 or
mutant protein. Migration of size standards (in kDa) is indicated to the
left. (C) YFV present in the medium was enumerated by plaque assay.
Data represent mean values obtained from triplicate wells; error bars
indicate the standard deviation. Pfu, plaque forming units.
doi:10.1371/journal.ppat.1001255.g006
Figure 5. DNAJC14 inhibits a post entry step. (A) and (B) V1-GFP-
(GFP) or V1-hDNAJC14-FL (FL) transduced SW13 cells were electropo-
rated 2 d later with in vitro transcribed YF-17D RNA to bypass the entry
step. Cells and media were harvested at the indicated times after
electroporation. (A) Western blot analysis was performed on equal
volumes of the cell extracts using the antibodies indicated to the right;
actin serves as a loading control and antibodies to myc detect the
tagged DNAJC14 protein. Migration of size standards (in kDa) is
indicated to the left. (B) Virus present in the medium from V1-GFP- (GFP,
black circles) and V1-hDNAJC14-FL (FL, red triangles) transduced cells
was enumerated by plaque assay. A single separate well was utilized for
each time point. Pfu, plaque forming units. (C) Schematic of the YFV
replicon construct, which expresses Renilla luciferase (RLuc) in place of
the structural proteins. The locations of the YFV nonstructural proteins
are indicated in the polyprotein, which is targeted to the ER by a signal
sequence (red bar). UTR, untranslated region; 2A (black bar), the foot
and mouth disease virus 2A autoproteolytic peptide. (D) V1-GFP- (GFP,
circles) and V1-hDNAJC14-FL- (FL, triangles) transduced SW13 cells were
electroporated with the wild type YF replicon RNA (filled symbols, solid
lines) or with replication incompetent RNA containing a mutation in the
RNA-dependent RNA polymerase (DDD, open symbols, dashed lines). At
various times after electroporation, the cells were harvested and
luciferase activity was determined. Data represents the mean luciferase
value of triplicate samples; error bars indicate the standard deviation
and are sometimes obscured by the symbol. RLU, relative light units.
Similar results were obtained in an independent experiment utilizing
Huh7.5 cells.
doi:10.1371/journal.ppat.1001255.g005
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production due to a requirement for uncleaved NS2-3 for late life
cycle events [48]. In contrast, in the case of YFV, DNAJC14
overexpression inhibits RNA replication (Figure 5D). Based on this
apparent opposite effect, we wondered if DNAJC14 might inhibit
(rather than enhance) YFV NS2B-3 cleavage and result in reduced
levels of subsequent RNA replication. It is of interest that for YFV,
cleavage at the NS2B/3 site is mediated by the viral NS3 protease,
while for HCV the cleavage of the NS2/3 site is mediated by NS2.
Since the effects of DNAJC14 on cleavage at the NS2/3 site of
BVDV was successfully determined by coexpression of DNAJC14
and viral fragments capable of self-cleavage [39], we took a similar
approach to test whether DNAJC14 inhibited YFV NS2B-3
cleavage. We first generated a doxycycline-inducible cell line
expressing hDNAJC14 mutant NT5 with a C-terminal myc tag
(Figure 8A). As expected, YFV replication was reduced in this cell
line when treated with doxycycline to induce hDNAJC14-NT5
expression (Figure 8B). Using transfection, we expressed Flag-
tagged self-cleavage competent YFV NS2B-3181 as well as a form
incapable of cleavage due to a S138A active site mutation within
NS3 [49] and monitored cleavage in doxycycline treated
(expressing hDNAJC14-NT5) or non-induced control cells by
Western blot. Similarly, we expressed Flag-tagged self-cleavage
competent HCV NS2-3 protease, as well as a form incapable of
autocleavage due to a H143A active site mutation within NS2
[11]. A plasmid expressing GFP was cotransfected to monitor
transfection efficiency. As shown in Figure 8C, wildtype NS2B-3
or NS2-3 was efficiently processed resulting in similar levels of NS2
in the presence or absence of DNAJC14-NT5. The low levels of
cleavage incompetent HCV NS2B-3 are likely due to the
previously described rapid degradation of uncleaved NS2-3 [50].
Thus, contrary to our prediction, DNAJC14 does not grossly
inhibit YFV, or HCV polyprotein cleavage. However, due to the
sensitivity of this assay, subtle inhibition of processing efficacy
would likely not be detected. Moreover, given the efficiency of
cleavage in cells not induced to express DNAJC14, we cannot
exclude an enhancement effect, similar to that seen with BVDV
NS2-3 processing, of DNAJC14 on YFV NS2B-3 or HCV NS2-3
cleavage.
DNAJC14 is recruited to YFV replication complexes
Since DNAJC14 does not inhibit YFV genome translation yet
blocks RNA replication, we wondered if it might interfere with the
formation of functional replication complexes, which assemble on
ER-derived membranes. Studies to investigate whether
hDNAJC14 colocalizes with replication complexes in YFV
infected cells are complicated by the fact that DNAJC14
expression inhibits YFV replication. To determine whether
hDNAJC14 colocalizes with YFV replication complexes, we made
use of the non-inhibitory DNAJC14 mutants H471Q and CT1
and monitored their colocalization with YFV NS3. SW13 cells
transduced with lentiviruses expressing hDNAJC14 mutants were
infected with YFV and the localization of NS3 and hDNAJC14
was examined by confocal microscopy (Figure 9A). As a control,
we examined the localization of calnexin and demonstrated that
YFV infection results in a redistribution of this ER marker to
colocalize with NS3 in infected cells (Figure 9A). Full-length
DNAJC14 containing the J domain mutation H471Q (FL-
H471Q) and mutant CT1 both colocalized with NS3 in infected
cells. The results are consistent with the known ER reorganization
that occurs during YFV replication complex formation and
suggest that DNAJC14 proteins associated with the ER membrane
redistribute to replication complexes during YFV infection.
Expression levels of the CT1 mutant, which is recruited to sites
containing NS3 (Figure 9A) without blocking replication
(Figure 6C), are similar to expression levels of the inhibitory full-
length protein (Figure 6B). This makes a nonspecific process, such
as the induction of ER stress due to protein overexpression,
unlikely for the inhibitory mechanism.
To assess further whether DNAJC14 associates with the viral
replication complexes, we looked for a physical interaction using
coimmunoprecipitation. Cells transduced (or not) to express the
myc epitope tagged noninhibitory CT1 mutant were infected with
YFV. CT1 and associated proteins were isolated from lysates using
anti-myc antibody. As can be seen in Figure 9B, NS3 was
coimmunoisolated with CT1, while the ER marker calnexin was
not. Thus while both calnexin and CT1 colocalize with NS3 in
immunofluorescence assays (Figure 9A), NS3, but not calnexin,
was found to be in a physical complex with CT1. We utilized
Figure 7. The C-terminus of DNAJC14 mediates self-interaction. (A) Self-interaction of DNAJC14. HEK293T cells were cotransfected with
pTrip-EGFP-hDNAJC14-NT5 (GFP-NT5) and pV1-hDNAJC14-FL (FL-myc) or the NT5 mutant (NT5-myc) as indicated. Cells were harvested 2 d later and
myc-tagged DNAJC14 was immunoprecipitated using anti-myc antibody. Western blots were performed using anti-GFP and anti-myc antibodies as
indicated. (B). Self-interaction is mediated by the C-terminus. HEK293T cells were cotransfected as indicated with pTrip-EGFP-hDNAJC14-NT5 (GFP-
NT5) and pV1-hDNAJC14-NT5 (NT5-myc, left panels) or the NT5CT1 mutant (NT5CT1-myc, right panels) lacking the C terminal 77 amino acids. Cells
were harvested 2 d later and DNAJC14 was immunoprecipitated using anti-GFP or control IgG as indicated. Western blots were performed using anti-
GFP and anti-myc antibodies as indicated. For both A and B, arrows indicate the DNAJC14 proteins; migration of size standards (in kDa) is indicated to
the left. The asterisk indicates immunoglobulin heavy chain.
doi:10.1371/journal.ppat.1001255.g007
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replication complexes and assess whether endogenous DNAJC14
is present (Figure 9C). Using anti-DNAJC14 antibody, we found
that in uninfected cells, endogenous DNAJC14 in the cytosol
predominantly displayed a diffuse pattern with occasional punctate
staining. In infected cells the endogenous DNAJC14 demonstrated
a more punctate staining pattern and the dsRNA was found
colocalized with these punctate sites of staining. These findings
demonstrate that both endogenous DNAJC14 and overexpressed
non-inhibitory DNAJC14 mutants are recruited to YFV replica-
tion complexes, which suggests that endogenous DNAJC14 may
facilitate replication complex formation.
Endogenous DNAJC14 facilitates YFV
To test whether DNAJC14 might be required for, or facilitate
virus replication, we used siRNA-mediated silencing to reduce
levels of endogenous DNAJC14 and tested the ability of YFV to
replicate. To evaluate replication capacity across a range of
DNAJC14 levels, we used cells transduced with vector as well as
cells transduced with lentivirus expressing DNAJC14 and
subjected them to silencing with a control irrelevant siRNA or
siRNA targeting DNAJC14 mRNA within the protein coding
region. It should be noted that the absolute level of DNAJC14
RNA in normal cells (vector-transduced cells treated with control
siRNA) is low, with DNAJC14 RNA levels more than 1000 fold
lower than GAPDH mRNA levels (data not shown). Reducing
levels of DNAJC14 mRNA by ,2 fold, as measured by
quantitative RT-PCR (Figure 10A), resulted in a ,4 fold
statistically significant (p,0.0001) reduction in YFV titer
(Figure 10B, compare vector cells treated with the control and
DNAJC14 siRNAs). Western blot analysis using anti-DNAJC14
antibody demonstrates a reduction upon silencing at the protein
level as well (Figure 10C). Although no protein band is apparent in
the vector cells treated with the DNAJC14-targeting siRNA, given
that mRNA was still detectable, a low level of residual protein
could account for the modest reduction in viral replication.
Despite multiple attempts we were unable to reduce the DNAJC14
mRNA levels lower than ,2 fold (data not shown). Interestingly,
cells transduced with lentivirus expressing DNAJC14 had a .300
fold increase in the level of DNAJC14 mRNA (Figure 10A,) and a
corresponding increase in DNAJC14 protein levels (Figure 10C),
which resulted in a ,15 fold inhibition of YFV virion production
(Figure 10B, compare vector and DNAJC14 cells treated with the
control siRNA). Silencing of DNAJC14 in the DNAJC14-
overexpressing cells resulted in intermediate mRNA (Figure 10A)
and protein (Figure 10C) levels, although the RNA levels remained
,50–60 fold higher than endogenous levels (compare DNAJC14
siRNA-treated DNAJC14 cells to control siRNA-treated vector
cells). This residual intermediate level of DNAJC14 was less
inhibitory than the high levels present in DNAJC14 overexpress-
ing cells treated with the control siRNA, but still resulted in a 4.7
fold inhibition of YFV replication compared to vector cells treated
with the control siRNA (Figure 10B). Thus decreasing DNAJC14
levels by ,2 fold or increasing levels by ,50 fold each had a
similar (,4 fold) inhibitory effect towards YFV. Thus maximal
YFV replication requires an optimal DNAJC14 concentration;
levels too low or too high result in inhibition.
The antiviral activity of DNAJC14 occurs in a temporal
and dose-dependent manner
A requirement for an optimal level of DNAJC14 and the ability
of overexpressed wildtype DNAJC14 to inhibit YFV replication
could be explained by DNAJC14 facilitating YFV replication
complex formation in a stoichiometric process such that increased
levels might function in a dominant negative fashion to inhibit
replication complex formation. There is precedent for this, since
DNAJC14 modulates BVDV NS2-3 cleavage in a temporal
manner due to a stoichiometric mechanism [40,41]. After
translation of the BVDV polyprotein, NS2-3 autoprocessing is
mediated in cis by the cysteine protease residing in NS2 [41],
which requires DNAJC14 in a 1:1 ratio [40]. RNA replication is
dependent on this cleavage, due to a requirement for free NS3 for
the formation of functional replication complexes [41]. Limiting
amounts of cellular DNAJC14 thus limit processing and result in
downregulation of RNA replication at later time points, allowing
viral persistence [40]. Overexpression of DNAJC14 results in
increased cleavage at NS2/3, increased RNA replication, and
increased cytopathogenicity [39].
We wondered if inhibition of YFV might exhibit similar
properties, in which the ratio of DNAJC14 to viral substrate is
critical for its antiviral activity. If so, then inhibition would be
expected to be dose-dependent, and continued translation of the
incoming genome over time might restore the appropriate
stoichiometry and thus allow replication to begin. Consistent
Figure 8. DNAJC14 does not inhibit NS2/3 cleavage of YFV and
HCV. YFV replication is inhibited in cells inducibly expressing the NT5
mutant form of DNAJC14. (A) T-REx-293-NT5 cells were left uninduced
or induced by treatment with doxycycline (Dox) for the indicated h and
lysates were analyzed by Western blot using anti-myc and anti-actin
(loading control) antibodies. Migration of size standards (in kDa) is
indicated to the left. (B) T-REx-293-NT5 (NT5) or T-REx-293-LacZ (LacZ)
cells were induced to express DNAJC14-NT5 or b-galactosidase,
respectively, by 24 h treatment with doxycycline. The cells were then
infected with YFV (moi=5) and the medium was harvested and
replaced at each timepoint. Virion production since the prior time point
was enumerated by plaque assay. Pfu, plaque forming units. (C) YFV
and HCV NS2/3 cleavage in T-REx-293-NT5 cells. T-REx-293-NT5 cells
were left untreated or were induced to express DNAJC14-NT5 by 24 h
treatment with doxycycline (Dox) as indicated. The cells were then
cotransfected with pEGFP (loading control) and either pFlag-HCV-NS2/
3(181) or pFlag-YFV-NS2/3(181). As controls, NS2-3 proteins containing
active site mutations in the HCV NS2 (H143A) or YFV NS3 (S138A)
proteases and incapable of cleavage activity were also expressed as
indicated. Cells were harvested 1 day later and analyzed by Western
blot using anti-Flag antibody (top panel) or anti-myc and anti-GFP
antibodies (bottom panel). Arrows indicate the migration of the
relevant proteins and migration of size standards (in kDa) is indicated
on the left.
doi:10.1371/journal.ppat.1001255.g008
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PLoS Pathogens | www.plospathogens.org 12 January 2011 | Volume 7 | Issue 1 | e1001255Figure 9. DNAJC14 is recruited to YFV replication complexes. (A) SW13 cells were left untransduced (top row) or were transduced (lower 2
rows) with the noninhibitory V1-hDNAJC14 mutants FL-H471Q or CT1 as indicated. Two d later the cells were mock treated (left panels) or were
challenged with YFV (moi=5, right 3 panels). After an additional 2 d, the cells were fixed and immunostained with rabbit anti-YFV NS3 polyclonal
antibodies (NS3), and mouse anti-calnexin antibody (calnexin) or mouse anti-myc monoclonal antibody (myc) as indicated. AF488-conjugated anti-
mouse IgG and AF594-conjugated anti-rabbit IgG antibodies were used as secondary antibodies. The cells were analyzed by confocal microscopy and
representative images are shown. Calnexin or DNAJC14 mutants are shown in green, YFV NS3 is shown in red, and the merged images are shown on
the right. (B) SW13 cells were left untransduced or were transduced with the V1-hDNAJC14-CT1 mutant (CT1-myc) as indicated and were infected 2 d
later with YFV (moi=1). After 2 d of infection, myc-tagged DNAJC14-CT1 was immunoprecipitated using anti-myc antibody. Western blots were
performed using antibodies against NS3, calnexin and the myc epitope tag as indicated. (C) SW13 cells were left uninfected or were infected with YFV
(moi=1) as indicated. The cells were fixed 1 d later and analyzed by confocal microscopy for endogenous DNAJC14 (red) and double stranded RNA
(dsRNA, green). The merged image is shown on the right. Arrows indicate several areas of colocalized DNAJC14 and dsRNA.
doi:10.1371/journal.ppat.1001255.g009
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DNAJC14 diminished at later times after infection or electropo-
ration (Figures. 4A, 5B). To test this hypothesis, we monitored the
antiviral activity of DNAJC14 at the single cell level by flow
cytometry. Cells transduced with RFP-tagged DNAJC14 (full-
length and NT1 mutant) were infected with a YFV variant
expressing Venus, and both virus replication (Venus) and
DNAJC14 expression (RFP) were monitored. As shown in
Figure 11A, the YFV signal was dramatically reduced in RFP-
DNAJC14-FL- and -NT1-expressing cells compared to levels
seen in cells expressing ZAP, an anti-Sindbis virus protein with no
effect on YFV [10,51]. In addition, the NT1 mutant demon-
strated more potent inhibitory activity than full-length
DNAJC14, which may be due to higher expression levels of
NT1 as reflected by the RFP signal. Interestingly, both full-length
and the NT1 mutant inhibited YFV in a dose dependent manner
(Figure 11A), with lower YFV (Venus) signal seen in cells
expressing higher levels of DNAJC14 (RFP). We next investigated
the antiviral activity of mutant NT1 at various time points after
infection (Figure 10B). At late time points (4 d), substantial YFV
(Venus) signal was detected in RFP-positive cells. Even at this late
time, when substantial YFV replication was occurring, the
inhibition mediated by NT1 was still dose-dependent. To verify
that increased Venus expression was due to increased replication,
in a separate experiment we monitored infectious virus
production in cells expressing RFP-DNAJC14-NT1 compared
to nontransduced cells. Virion production on day 4 was found to
be equivalent (Figure 10C), despite the fact that the DNAJC14
overexpressing cells were more resistant to cell death as
monitored by crystal violet staining (data not shown). To exclude
the possibility that the increase in virus replication seen after 3 to
4 d is due to the generation and replication of escape mutants, we
collected the culture medium from cells after 4 d of infection and
re-infected new cells expressing RFP-DNAJC14-NT1. Infection
with this virus resulted in a similar early inhibition with a time-
dependent increase in virus replication (data not shown). These
results demonstrate that not only is DNAJC14-mediated
inhibition dependent on the level of DNAJC14, but with time,
levels that initially blocked YFV replication no longer are
inhibitory. The failure to observe YFV replication in the Rd 3
cells (Figure 3A) is likely due to the fact that these cells had
undergone prior infection and selection, resulting in a population
of cells with maximal inhibitory properties.
Discussion
DNAJC14 (also designated DRIP78, Jiv and HDJ3) is a
member of the Hsp40 family of protein chaperones [45,52].
Proteins in this family contain a 70 amino acid motif, designated
the J-domain, which recruits Hsp70 family members and
stimulates the ATP hydrolysis step of the chaperone process. J-
domain containing proteins are involved in diverse cellular
processes. The human DNAJC family has 23 members with the
presence of the J domain being the single common feature.
Although not extensively studied, involvement of these proteins in
Figure 10. Modulation of DNAJC14 levels by siRNA alters YFV
replication. SW13 cells transduced with V1-GFP (Vector) or V1-
hDNAJC14-FL (DNAJC14) were treated with irrelevant control siRNA or
siRNA targeting DNAJC14 as indicated and were infected with YFV
(moi=5). After 24 h the medium from triplicate samples was collected
for virus titration, while 2 samples were pooled for RNA isolation and
cells in the remaining sample were harvested for Western analysis. (A)
DNAJC14 RNA levels were determined by quantitative RT-PCR. For each
sample, DNAJC14 RNA levels were normalized to levels of GAPDH RNA
and the ratio present in the vector control cells treated with the
irrelevant control siRNA was set to 1. Bars represent mean relative levels
obtained from triplicate RT reactions; error bars indicate the standard
deviation. Asterisks indicate a significant difference from the cells
transduced with control vector and receiving the control siRNA
(students t test; *p,0.05, **p,0.01, ***p,0.001). (B) Virus present in
the medium was titered by plaque assay. Bars represent mean titers
from triplicate samples; error bars indicate the standard deviation. Pfu,
plaque forming units. Asterisks indicate a significant difference in virus
production compared to cells transduced with control vector and
receiving the control siRNA (students t test; ***p,0.001). Virus titers
obtained after silencing DNAJC14 in the vector control versus DNAJC14
transduced cells were not statistically different (ns). (C) Western blot
analysis was performed on the silenced samples using the indicated
antibodies. Whether the cells were transduced with V1-hDNAJC14-FL
(DNAJC14-myc+) or control vector (2) is indicated. Migration of size
markers (in kDa) is indicated to the left. The asterisk indicates a non-
specific band.
doi:10.1371/journal.ppat.1001255.g010
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been noted [45]. DNAJC14 has previously been implicated in the
life cycle of a member of the Flaviviridae. The bovine homolog of
this factor, Jiv, is essential for the polyprotein cleavage and
replication of the pestivirus BVDV. Jiv acts as a required co-factor
for the viral NS2 autoprotease, influencing its cleavage from NS3
and modulating RNA replication, virus production and cytopath-
ogenicity of this pestivirus [38,39,42]. In contrast to our findings
with YFV, increased expression of Jiv results in higher levels of
BVDV RNA replication and virus-induced cell death. Interest-
ingly, some cytopathic biotypes of BVDV are naturally occurring
recombinant viruses, which have insertions of DNAJC14 in the
NS2-3 coding region. A 90 amino acid domain common to all of
the Jiv-containing cytopathic BVDV isolates is designated Jiv90
(see Figure 2D). This sequence is distinct from the J-domain and
contains two conserved CXXCXXXH motifs.
DNAJ proteins regulate the ATPase cycle of Hsp70 via their J
domain, with the HPD motif critical in accelerating the Hsp70
ATPase activity, while the substrate-binding domain loads the
substrate onto Hsp70 [53,54]. Our studies with mutant H471Q
suggest that the critical HPD motif within the J domain is required
for DNAJC14 antiviral function, suggesting that ATP-driven
Hsp70 chaperone activity may be involved in the process of RNA
replication and its inhibition. Since Hsp70 chaperone activity
occurs via a stoichiometric mechanism, with a single Hsp70
monomer per substrate [54] it seems likely that DNAJC14/Hsp70
chaperone activity is required for YFV replication complex
assembly and that overexpression of DNAJC14 disrupts the
chaperone/substrate complex. Dimerization of some Hsp40
family members is evolutionarily conserved and required for their
function [45,53]. The CT1 mutant lacks the ability to multimerize
(Figure 8) and fails to inhibit YFV (Figure 6) as well as HCV (data
Figure 11. DNAJC14 inhibits YFV in a temporal and dose-dependent manner. (A) SW13 cells were mock transduced (Mock) or transduced
with Trip-RFP-hNZAP (NZAP), Trip-RFP-hDNAJC14-FL (FL) or Trip-RFP-hDNAJC14-NT1 (NT1) and infected 2 d later with YFV-Venus (moi=5). Cells were
fixed at 1.5 d post infection and analyzed by flow cytometry. The Venus (y-axis) and RFP (x-axis) fluorescence intensities of the cells are shown; gates
to indicate expression of the transduced protein or productive infection were set on Mock transduced, uninfected cells (not shown). (B) SW13 cells
were transduced with Trip-RFP-hDNAJC14-NT1 and infected 2 d later with YFV-Venus (moi=5) and analyzed as in (A) at the indicated days after
infection. (C) SW13 cells were left untransduced (closed circles) or were transduced with Trip-RFP-hDNAJC14-NT1 (RFP-NT1, open circles) and infected
2 d later with YFV-Venus (moi=5). At the indicated times, the medium was removed and YFV present in the medium was quantified by plaque assay.
Each data point represents the mean titer obtained from duplicate wells; error bars indicating the range are obscured by the symbols. The dotted line
indicates the sensitivity of the plaque assay.
doi:10.1371/journal.ppat.1001255.g011
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antiviral function.
In our studies, we demonstrated that DNAJC14 noninhibitory
mutants are found in YFV replication complexes, as measured by
colocalization and coprecipitation with NS3 (Figure 10A and B).
Moreover, endogenous DNAJC14 rearranges upon YFV infection
and is found colocalized with active replication complexes, as
determined by the presence of dsRNA (Figure 10C). This suggests
that YFV replication complexes assemble at a specific ER
membrane site where DNAJC14 is located, and that DNAJC14
(and likely Hsp70) is specifically recruited to facilitate formation of
the viral replication complex. DNAJC14 overexpression would
then result in disrupted chaperone/substrate stoichiometry and
inhibit replication complex assembly. Alternatively, YFV may
hijack DNAJC14-containing membranes for its replication
complex assembly, and overexpression may inhibit the distribution
and recruitment of other host factors localized to this membrane
microdomain and required for replication complex formation.
We realized that the inhibitory effect of DNAJC14 on YFV was
diminished at later time points post infection and that inhibition
was dose dependent, with higher levels of DNAJC14 resulting in
lower levels of virus replication (Figure 11). One possible
explanation is that at early time points, overexpressed DNAJC14
is in vast excess to its substrates (viral proteins) and this
inappropriate stoichiometry results in inhibition of replication
complex formation. Since DNAJC14 does not inhibit virus
genome translation (Figure 5D), nor polyprotein processing
(Figure 8C), viral protein would be predicted to accumulate with
time. At some point, the level of viral protein(s) would result in an
appropriate DNAJC14 to substrate ratio to allow the chaperone
process to occur and thus overcome DNAJC14’s inhibitory effect.
This is not dissimilar to the scenario occurring with BVDV, in
which the DNAJC14 Jiv90 domain interacts with BVDV NS2-3 at
a ratio of 1:1. This stoichiometric mechanism might be a common
requirement for normal DNAJC14 cellular function, as either
overexpression or sequestration of DNAJC14 inhibits dopamine
D1 receptor transport [44].
We found that multiple Flaviviridae were inhibited under
conditions of DNAJC14 overexpression and wondered whether
viruses from other families might be similarly affected. We tested
DNAJC14’s effects on Sindbis virus, a positive strand RNA virus
from the Alphavirus genus. In contrast to the flaviviruses, we found
that DNAJC14 overexpression had no effect on viral replication,
as measured by expression of a fluorescent reporter from the viral
subgenomic RNA (data not shown). Thus replication complex
formation for Sindbis virus is not likely affected by DNAJC14
overexpression. Interestingly, however, Sindbis virion production
was reduced by DNAJC14 overexpression (data not shown). Thus
a step in Sindbis virus assembly, such as glycoprotein maturation
and transport from the ER-Golgi to the plasma membrane, where
Sindbis budding occurs, may require DNAJC14-containing
membrane microdomains and chaperone function. In addition,
overexpression of DNAJC14 reduced VSV virion production (data
not shown), suggesting an effect on VSV glycoprotein ER-golgi
transport. Since it has been reported that DNAJC14 is involved in
dopamine D1 receptor transport [44], it is likely that DNAJC14
facilitates specific membrane processes including vesicle transport
and viral replication complex assembly. It is possible that many
Figure 12. Proposed model of DNAJC14 function. (A) Incoming viral RNA is translated to produce the inactive form(s) of a viral protein(s)
required for RNA replication complex formation (A and B, yellow and brown stars). When the stoichiometry of the substrate protein(s) and the host
chaperone machinery, consisting of DNAJC14 (DNAJ, blue) and Hsp70 (green), is appropriate, proper folding (AB) allows the formation of replication
complexes which generate new progeny viral RNA. This RNA is further translated to produce more substrate, which after undergoing the chaperone
process results in the formation of additional replication complexes and amplification of the RNA replication process. Overexpression of DNAJC14
mutants (red) lacking the C-terminal self-interaction domain (CT mutants), or with mutations in the J domain (H471Q, L466P) has no effect on viral
replication, since the mutants lack features necessary for stable interaction and the chaperone complex is not disrupted. (B) Overexpression of full-
length DNAJC14 (FL) or N-terminal truncation mutants (NT mutants) results in their incorporation into the chaperone complexes due to the presence
of the C-terminal interaction domain and an intact J domain. Disruption of the normal stoichiometry of the substrate/chaperone complex results in a
failure to properly fold the viral protein and a failure to generate replication complexes. With time, however, continued translation of the incoming
genome results in increased concentrations of the viral protein. The appropriate stoichiometry is restored allowing the chaperone process to proceed
and viral replication complexes to be generated.
doi:10.1371/journal.ppat.1001255.g012
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at various steps in their life cycle. Understanding these
requirements and identifying the chaperones and proteins
undergoing the chaperone process may lead to insights into
similarities and differences between different virus families in these
critical life cycle steps.
DNAJC14 can both facilitate and inhibit YFV replication.
Based on all of our findings, we propose the following model
(Figure 12): Translation of the incoming YFV RNA and
subsequent polyprotein processing generates the viral proteins
necessary for the viral RNA replication process. DNAJC14
functions as a chaperone system, most likely with involvement of
Hsp70, to facilitate a step in the YFV membrane-associated
multiprotein complex assembly that is critical for the formation of
replication complexes. The TM domains within DNAJC14 target
the protein to a specific subcellular ER membrane location,
wherein substrate selection and YFV replication complex
formation occurs. Multimerization of DNAJC14 via its C-terminus
is likely required for assembly of the chaperone/substrate complex.
It is possible that each DNAJC14 monomer binds a substrate and
together they promote the proper folding and interaction of the
substrate pair, which might be different sites on the same protein,
two different YFV proteins, or a viral protein and host protein
necessary for viral replication. Newly generated viral RNA is
produced, which after translation generates new substrate for the
chaperone process, and the formation of additional replication
complexes. Overexpression of DNAJC14 mutants that fail to
multimerize (CT1, CT2, CT3, CT4 or CT5), or contain
mutations in the critical J domain (L466P, H471Q, Figure 12A)
has no effect on virus replication; these mutants fail to interact with
and disrupt the normal chaperone components and therefore
exhibit no antiviral activity. Expression of full-length (wildtype)
DNAJC14 results in an excess of DNAJC14 relative to the
substrate, and complexes with an inappropriate stoichiometric
ratio are formed, disrupting the chaperone process (Figure 12 B).
The N-terminal truncation mutants, which contain the C terminal
multimerization motif and an intact J domain, also interact with
the chaperone components, disrupting the proper chaperone/
substrate stoichiometry. With time, continued translation of the
incoming viral genome (or genome generated by very low levels of
viral replication) results in the accumulation of viral proteins. Once
the optimal substrate/chaperone ratio is established, the restored
chaperone process results in replication complex formation and
viral RNA replication. Further studies are required to address the
viral and cellular substrate(s) for DNAJC14 and to determine if
other host factors (for example, Hsp70) participate in this
important chaperone process.
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